Of note, a recently closed phase 3 clinical trial regarding the effect of Lutetium-177–PSMA-617 prolonged progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer [32]. This evidence concerns the gene FOLH1 and prostate cancer.